UBS Investment Research

In a report published Friday, UBS Investment Research analyst William A. Featherston reiterated a Buy rating on Southwestern Energy (NYSE: SWN), and raised the price target from $41.00 to $45.00. In the report, UBS Investment Research noted, “2Q clean EPS/CFPS of $0.54/$1.39 compares to...

In a report published Friday, UBS Investment Research analyst Marc Goodman reiterated a Buy rating on Mylan (NASDAQ: MYL), and raised the price target from $36.00 to $39.00. In the report, UBS Investment Research noted, “Mgt did a good job detailing key drivers (injectables, respiratory, ARV,...

In a report published Friday, UBS Investment Research analyst Alex Kramm reiterated a Buy rating on MSCI (NYSE: MSCI), and raised the price target from $38.00 to $41.00. In the report, UBS Investment Research noted, “MSCI posted a solid beat and highlighted innovation, integration, and an...

In a report published Friday, UBS Investment Research analyst David Goldberg reiterated a Buy rating on Mohawk Industries (NYSE: MHK), and raised the price target from $140.00 to $150.00. In the report, UBS Investment Research noted, “Mohawk reported 2Q EPS of $1.84, ex one-time items related...

In a report published Friday, UBS Investment Research analyst Shneur Z. Gershuni reiterated a Neutral rating on Magellan Midstream Partners (NYSE: MMP), and raised the price target from $52.00 to $55.00. In the report, UBS Investment Research noted, “MMP reported 2Q13 EPU of $0.68 and EBITDA of...

In a report published Friday, UBS Investment Research analyst Eric J. Sheridan reiterated a Neutral rating on LinkedIn (NYSE: LNKD), and raised the price target from $180.00 to $230.00. In the report, UBS Investment Research noted, “LinkedIn delivered a better than expected result, but for the...

In a report published Friday, UBS Investment Research analyst Matthew Roden reiterated a Buy rating on Incyte (NASDAQ: INCY), and raised the price target from $27.00 to $28.00. In the report, UBS Investment Research noted, “We've felt all year that Incyte has had the data it needs to improve...

In a report published Friday, UBS Investment Research analyst Steven Fisher reiterated a Buy rating on Fluor (NYSE: FLR), and raised the price target from $73.00 to $75.00. In the report, UBS Investment Research noted, “FLR discussed some 2013 prospects (CP Chem, Sasol cracker, Shell Franklin,...

In a report published Friday, UBS Investment Research analyst Julien Dumoulin-Smith reiterated a Neutral rating on Edison International (NYSE: EIX), and raised the price target from $47.00 to $49.00. In the report, UBS Investment Research noted, “Rate base guidance was slightly higher than our...

In a report published Friday, UBS Investment Research analyst Julien Dumoulin-Smith reiterated a Sell rating on Dynegy (NYSE: DYN), but lowered the price target from $20.00 to $18.00. In the report, UBS Investment Research noted, “We are lowering our ‘13/'14/'15 EBITDA estimates (pro forma...

In a report published Friday, UBS Investment Research analyst William A. Featherston reiterated a Sell rating on ConocoPhillips (NYSE: COP), and raised the price target from $54.00 to $57.00. In the report, UBS Investment Research noted, “Key conference call takeaways: 1) ‘13 production...

In a report published Friday, UBS Investment Research analyst Alex Kramm reiterated a Buy rating on CME Group (NASDAQ: CME), but lowered the price target from $84.00 to $83.00. In the report, UBS Investment Research noted, “Despite solid 2Q results CME declined some 3% today. We believe...

In a report published Friday, UBS Investment Research analyst Steven Valiquette reiterated a Buy rating on Cardinal Health (NYSE: CAH), and raised the price target from $53.00 to $58.00. In the report, UBS Investment Research noted, “In our view, a key takeaway from the CAH F4Q13 conf call is...

In a report published Friday, UBS Investment Research analyst Brian MacArthur reiterated a Neutral rating on Barrick Gold (NYSE: ABX), and raised the price target from $16.50 to $17.50. In the report, UBS Investment Research noted, “Barrick reported a headline loss of $8.55/share, however after...

In a report published Friday, UBS Investment Research analyst Eric J. Sheridan reiterated a Buy rating on Activision Blizzard (NASDAQ: ATVI), and raised the price target from $17.00 to $21.00. In the report, UBS Investment Research noted, “Activision delivered revs and EPS in line with its...